Theravance Biopharma, Inc. (TBPH)
Fuera de horario:
Theravance Biopharma, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080
United States
650 808 6000
https://www.theravance.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 99
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Rick E. Winningham M.B.A. | Chairman & CEO | 1.3M | N/D | 1960 |
| Mr. Aziz Sawaf C.F.A. | Senior VP & CFO | 583.5k | N/D | 1982 |
| Mr. Stuart Knight | VP of IT&I and Chief Information Officer | N/D | N/D | N/D |
| Ms. Gail B. Cohen | Vice President of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Brett A. Grimaud Esq. | Senior VP, General Counsel & Secretary | N/D | N/D | 1974 |
| Ms. Rhonda F. Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | 942.81k | N/D | 1965 |
| Ms. Stacy L. Pryce | Senior VP & Chief Strategy Officer | N/D | N/D | N/D |
| Dr. Aine Miller Ph.D. | SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office | N/D | N/D | N/D |
Descripción
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Theravance Biopharma, Inc. a partir del 1 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 6; Compensación: 8.
